Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)

SHE:002900 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,029	1,071	1,153	1,008	910.39	1,333
Other Revenue	61.64	61.64	34.09	20.27	35.41	5.72
Revenue	1,091	1,132	1,187	1,028	945.8	1,339
Revenue Growth (YoY)	-0.07%	-4.58%	15.40%	8.73%	-29.36%	-36.31%
Cost of Revenue	563.65	553.88	475.55	360.34	312.86	487.25
Gross Profit	527.04	578.6	711.23	668.08	632.94	851.63
Selling, General & Admin	412.67	432.05	598.15	594.6	667.1	734.35
Research & Development	99.3	105.22	112.81	89.27	99.92	112.02
Other Operating Expenses	9.94	7.39	11.1	15.53	14.14	15.77
Operating Expenses	522.93	545.88	719.2	699.98	782.97	865.92
Operating Income	4.1	32.72	-7.97	-31.91	-150.03	-14.29
Interest Expense	-31.56	-30.98	-22.89	-22.62	-13.8	-9.33
Interest & Investment Income	46.88	55.45	70.54	74.24	609.35	18.54
Currency Exchange Gain (Loss)	0.51	0.51	0.14	1.57	-0.02	-0.34
Other Non Operating Income (Expenses)	-1.08	3.63	-0.26	-1.06	-0.37	-0.46
EBT Excluding Unusual Items	18.85	61.34	39.56	20.22	445.12	-5.87
Gain (Loss) on Sale of Investments	-23.35	-14.64	13.37	13.87	-5.13	-37.36
Gain (Loss) on Sale of Assets	0	0.19	-2.61	-13.31	-1.92	-4.37
Asset Writedown	-2.94	-0	-0	-2.91	-0.68	-0.04
Other Unusual Items	13.17	13.11	31.06	22.2	15.45	80.79
Pretax Income	5.73	60.01	81.37	40.07	452.86	33.16
Income Tax Expense	-2.04	5.03	11.3	13.57	103.18	6.52
Earnings From Continuing Operations	7.77	54.98	70.08	26.5	349.68	26.63
Minority Interest in Earnings	3.27	3.7	3.58	3.71	1.27	2.69
Net Income	11.04	58.68	73.66	30.21	350.95	29.32
Net Income to Common	11.04	58.68	73.66	30.21	350.95	29.32
Net Income Growth	-79.28%	-20.35%	143.86%	-91.39%	1096.77%	-83.45%
Shares Outstanding (Basic)	311	309	307	302	311	326
Shares Outstanding (Diluted)	311	309	307	302	311	326
Shares Change (YoY)	0.24%	0.61%	1.61%	-2.74%	-4.68%	4.82%
EPS (Basic)	0.04	0.19	0.24	0.10	1.13	0.09
EPS (Diluted)	0.04	0.19	0.24	0.10	1.13	0.09
EPS Growth	-79.33%	-20.83%	140.00%	-91.15%	1155.56%	-84.21%
Free Cash Flow	-196.29	-315.52	-263.89	55.42	-86.48	-150.36
Free Cash Flow Per Share	-0.63	-1.02	-0.86	0.18	-0.28	-0.46
Dividend Per Share	0.200	0.200	0.200	0.100	0.320	0.080
Dividend Growth	-	-	100.00%	-68.75%	300.00%	-71.43%
Gross Margin	48.32%	51.09%	59.93%	64.96%	66.92%	63.61%
Operating Margin	0.38%	2.89%	-0.67%	-3.10%	-15.86%	-1.07%
Profit Margin	1.01%	5.18%	6.21%	2.94%	37.11%	2.19%
Free Cash Flow Margin	-18.00%	-27.86%	-22.23%	5.39%	-9.14%	-11.23%
EBITDA	105.15	133.24	90.43	65.02	-60.22	65.66
EBITDA Margin	9.64%	11.77%	7.62%	6.32%	-6.37%	4.90%
D&A For EBITDA	101.05	100.52	98.41	96.92	89.81	79.95
EBIT	4.1	32.72	-7.97	-31.91	-150.03	-14.29
EBIT Margin	0.38%	2.89%	-0.67%	-3.10%	-15.86%	-1.07%
Effective Tax Rate	-	8.38%	13.88%	33.87%	22.78%	19.68%
Revenue as Reported	1,091	1,132	1,187	1,028	945.8	1,339
Advertising Expenses	-	16.62	51.46	43.24	31.69	48.89

Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.